Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
August 10, 2022 09:00 ET
|
Arcutis Biotherapeutics, Inc.
Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly...
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
July 29, 2022 16:05 ET
|
Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Plaque Psoriasis Pipeline Analysis of 75+ Companies | DelveInsight
July 18, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 18, 2022 (GLOBE NEWSWIRE) -- Plaque Psoriasis Pipeline Analysis of 75+ Companies | DelveInsight Plaque psoriasis pipeline constitutes 75+ key companies continuously working...
Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
July 11, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studiesIf approved, roflumilast cream would be...
Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight
April 19, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 19, 2022 (GLOBE NEWSWIRE) -- Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight Plaque Psoriasis is the most common type of psoriasis...
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
March 25, 2022 07:30 ET
|
Arcutis Biotherapeutics, Inc.
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%),...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study
October 20, 2021 16:05 ET
|
Zai Lab Limited
Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque...
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
May 11, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...
Psoriasis Drugs Market To Reach USD 39.00 Billion By 2027 | Reports And Data
January 22, 2020 08:52 ET
|
Reports and Data
New York, Jan. 22, 2020 (GLOBE NEWSWIRE) -- The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027, according to a new report by Reports and Data. Psoriasis can be defined...